Back to Populer

FDA Updates Engagement Pathways for AI in Drug Development: A Generational Milestone

A #Generational moment, anticipated for more than a decade: The #FDA updated its formal engagement pathways for #AI in drug development. Pathes now exist for Generational #lineage management, #digital longevity, and precision #drug development. #Next-Gen #investors are taking action, while old-school waits on...

On May 28, 2026, TOWER shares with one of the most generationally consequential companies in #BioAI. They are already:

>Embedded in discovery pipeline of global pharma
>Trusted for safety and compliance with government research across continents
>Operating inside the FDA framework

This edge-case #innovation will reshape outcomes across generations. Participation in this session is intentionally limited to a select group of investors and families.

Sanskriti Thakur Vani Rao, CFA Stephanie Lasker Mark Sadovnick Katie Loeb Molayem Candice Matthews Brackeen Adi Soozin, MBA Christopher Alemán Ayelet Richter Isaac Bentwich L.R. Fox Shweta Jain BioAi ThinkTank BioAI Health Holland & Knight LLP Andy Moose Camir Ricketts Alyssa Morrow Frances Taheri Faizzan Ahmad, PhD(Oxon) LaToya Wilson Michael Meehan Pratik Gauri Sid Kapur TJ Sangani Neil Shapiro Christian Cantalupo Kathy Fernando Natasha Sunderji Karim Barrada Larissa Carrera James Kaplan Jason Feifer Renee Neri Olga Arakcheyev, CFA, CPA, ABV, CG Appraiser Arnav Field Judy Spalthoff Montero, CAP® Matthew Zimmerman, CFA

Shared byJordan Park - 18 days ago

Log in to comment
Loading ..